Introduction
Elevated serum levels of cardiac troponin T (cTnT) reflect myocardial damage, and the serum level of this protein was originally used as a marker to predict the prognosis of patients with acute coronary syndrome [1, 2] . Recently, the high-sensitive cTnT assay has been introduced in clinical settings [3] [4] [5] [6] , and with its introduction, it has become possible to detect even small elevations of the serum cTnT at a high sensitivity in the general population, and this parameter has been used as a marker to predict future cardiovascular events [3] [4] [5] [6] . However, the mechanisms underlying the minimal elevations of the serum TnT are not yet fully understood. On the other hand, increased arterial stiffness/abnormal central hemodynamics have been much focused on as independent risk factors for cardiovascular events [7] [8] [9] [10] . Bai et al. reported the existence of a correlation between increased arterial stiffness, as reflected by the carotid-femoral pulse wave velocity, and minimal elevations of the serum cTnT levels in elderly Chinese subjects [11] .
The Dallas Heart (DH) Study demonstrated that in middle-aged subjects aged 40-70 years, minimal elevations of the serum cTnT and elevated serum N-terminal fragment of B-type natriuretic peptide (NT-pro BNP) levels were independently predictive of future cardiovascular events [4] . The Atherosclerosis Risk in Communities (ARIC) Study also reported similar findings [5] . While several studies have demonstrated the existence of an association between increased arterial stiffness/abnormal central hemodynamics and elevated serum natriuretic peptide levels [12, 13] , no study has clarified the difference in the association with arterial stiffness/central hemodynamics between serum cTnT levels and serum NT-proBNP levels. Existence of such a difference might serve as at least one of the explanations for the independency of the predictive values of the two serum markers for future cardiovascular events.
Previously, we reported the existence of a significant relationship between the arterial stiffness/central hemodynamics and serum NT-proBNP levels in a middle-aged male worksite cohort [12] . Then, in the same cohort of our previous study (middle-aged male subjects working at a construction company), the present cross-sectional study was conducted to clarify whether increased arterial stiffness/abnormal central hemodynamics might be associated as strongly with minimal elevations of the serum cTnT levels as with elevations of the serum NTproBNP levels.
Methods

Study cohort
The present cross-sectional study was conducted in a worksite cohort composed of employees of a construction company located in downtown Tokyo. The study protocol has already been described in detail elsewhere [14] . The annual health checkup conducted in the morning in fasting subjects included physical examinations, blood pressure measurements (2 times) with the subjects in the seated position, blood and urine examinations, electrocardiography, chest roentgenography, barium swallow, audiometry, vision testing, and measurements of the brachial-ankle pulse wave velocity (brachial-ankle PWV) and radial augmentation index (radial AI). In 2012, in addition to these examinations, the serum cTnT levels and serum NT-pro BNP levels were also measured in all of the study subjects. Verbal informed consent for the measurements was obtained from all of the participants. The study was conducted with the approval of the Ethics Guidelines Committee of Tokyo Medical University.
Subjects falling under the following criteria were excluded from the study [12, 14, 15] : (1) ankle/brachial systolic blood pressure index of less than 0.95; (2) presence of atrial fibrillation; (3) standard deviation of the radial AI, calculated from ten radial pressure waveform records, exceeding 6%.
Of the 2870 employees who were working at either the office headquarters or branch offices of the company located in Tokyo, the data of 65 subjects were excluded because of the lack of availability of the complete data set. In addition, 57 subjects were excluded because they had an ankle/brachial systolic blood pressure index of less than 0.95 (n = 13), atrial fibrillation (n = 7), or a standard deviation of the radial AI of !6% (n = 37) (some of these subjects fulfilled more than two of the exclusion criteria). Furthermore, 374 women were excluded because the number of women in the study cohort was small. Finally, the data from 2374 men were included in the analyses.
Measurements Pulse wave velocity
The brachial-ankle PWV was measured using a volumeplethysmographic apparatus (Form/ABI, Colin Co. Ltd., Komaki, Japan), in accordance with a previously described methodology [12, 14] . In brief, occlusion cuffs, which were connected to both the plethysmographic and oscillometric sensors, were tied around both the upper arms and ankles of the subjects lying in the supine position. The brachial and post-tibial arterial pressures were measured using the oscillometric sensor. The measurements were conducted after the subjects had rested for at least 5 min in the supine position, in a temperature-controlled room (24-26 8C) designed exclusively for this purpose.
Augmentation index
Measurements of the blood pressure and radial AI were conducted after the subjects had rested for 5 min in the sitting position. The blood pressure was measured in the right upper arm using the oscillometric method (HEM-907; Omron Healthcare Co., Ltd., Kyoto, Japan). Immediately after this measurement, the left radial arterial waveform was recorded using an arterial applanation tonometry probe equipped with an array of 40 micropiezoresistive transducers (HEM-9010AI; Omron Healthcare Co., Ltd.). The HEM-9010AI device is programmed to automatically determine the pressure of the radial artery to yield the optimal radial arterial waveform [12, 15] . Then, the first and second peaks of the peripheral systolic pressure [SBP1, a marker of the brachial systolic blood pressure, and SBP2, a marker of the central systolic blood pressure (CSBP)] and peripheral diastolic pressure (DBP) were automatically detected using the fourth derivatives for each radial arterial waveform, and averaged. The radial AI, a marker of the central AI, was calculated as follows: (SBP2 À DBP)/ (SBP1 À DBP) Â 100 (%) [12, 15] . PP1 = SBP1 À DBP and PP2 = SBP2 À DBP, a marker of the central pulse pressure (CPP) were calculated [12, 15] . The mean blood pressure (MBP) was calculated as 1/3 of the (SBP1 À DBP) plus the DBP.
Laboratory measurements and definitions
The serum levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL) and creatinine (Crnn), and the fasting blood glucose (FPG) were measured enzymatically (Falco Biosystems Co. Ltd, Tokyo, Japan). Serum TnT levels were measured using the Elecsys 2010 Troponin T hs kit (Roche Diagnostics, Indianapolis, IN, USA) [16] . The lower limit of detection is 0.008 ng/mL, with a reported 99th percentile value in apparently healthy individuals of 0.014 ng/mL [16] . Serum NT-pro BNP levels were determined using a chemiluminescence immunoassay kit (Roche Diagnostics, Mannheim, Germany) [17] . All the blood samples were obtained in the morning after the patients had fasted overnight. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation for Japanese subjects [18] : eGFR = 194 Â Crnn À 1.094 Â Age À 0.287.
Two cut-off points each were used to define elevations of the serum TnT level (!0.014 ng/mL and !0.010 ng/mL) [4, 5, 16, 19] and elevation of the serum NTproBNP level (!125 pg/mL and !55 pg/mL) [17, 20] . Diabetes mellitus was defined as a history of receiving medication for diabetes mellitus and/or glycated hemoglobin A1C !6.5%. The current clinical histories of cardiovascular disease (coronary artery disease, other heart diseases, and/or stroke) were obtained by questionnaires.
Statistical analysis
Data are expressed as means AE SD. The relationships of the arterial parameters with elevation of the serum cTnT and NT-proBNP levels were assessed by binary logistic regression analyses. All of the analyses were conducted using the IBM/SPSS software for Windows, version 17.0J (IBM/SPSS Inc., Chicago, IL, USA); p-values < 0.05 were considered to denote statistical significance. Table 1 shows the clinical characteristics of the patients. The prevalence rates of elevated minimal elevations of the serum cTnT levels were as follows: 3.2% (76/2374) for the cut-off value of !0.010 ng/mL, and 1.1% (26/2374) for the cut-off value of !0.014 ng/mL. The prevalence rates of elevated serum NT-proBNP levels were as follows: 9.3% (221/2374) for the cut-off value of !55 pg/mL and 1.3% (31/2374) for the cut-off value of !125 ng/mL.
Results
In the binary logistic regression analyses, advanced age, reduced eGFR, elevated body mass index (BMI), and history of medication for hypertension had significant odds ratios for elevated serum cTnT levels (!0.014 ng/mL); advanced age, reduced eGFR, elevated BMI, reduced HDL, elevated SP1 (brachial systolic blood pressure), elevated PP1 (brachial pulse pressure), history of smoking, presence of diabetes mellitus, and history of medication for hypertension, dyslipidemia, and/or diabetes mellitus had significant odds ratios for elevated serum cTnT levels (!0.010 ng/mL) ( Table 2 ). When these parameters were simultaneously entered in the binary logistic regression analyses, advanced age, reduced eGFR, and elevated BMI were significant for serum cTnT levels !0.014 ng/mL, and advanced age, elevated BMI, and history of medication for diabetes mellitus were significant for serum cTnT levels !0.010 ng/mL (Table 2) . On the other hand, a history of cardiovascular disease was not associated with any significant elevation of the odds ratio for elevated cTnT levels.
For the case of elevated serum NT-proBNP levels, the binary logistic regression analyses revealed advanced age, reduced eGFR, elevated SP1, elevated PP1, history of smoking, and history of medication for hypertension, dyslipidemia, and/or cardiovascular diseases had significant odds ratios for elevated serum NT-proBNP levels !125 pg/mL; on the other hand, advanced age, reduced eGFR, elevated SP1, elevated PP1, history of smoking, and history of medication for hypertension and/or cardiovascular diseases had significant odds ratios for elevated serum NT-proBNP levels !55 pg/mL (Table 3 ). When these parameters were simultaneously entered in the binary logistic regression analyses, advanced age, reduced eGFR, history of smoking, and history of medication for cardiovascular diseases were significant for elevated serum NT-proBNP levels !125 pg/mL, and advanced age and history of medication for cardiovascular diseases were significant for elevated serum NT-proBNP levels !55 pg/mL ( Table 3) .
As shown in Table 4 , while elevated brachial-ankle PWV had a significant odds ratio for elevated serum cTnT levels (!0.010 ng/mL) in the absence of adjustments, these associations were no longer seen when the significant variables were entered simultaneously into a binary logistic regression analysis model. On the other hand, when the significant variables were entered simultaneously into a binary logistic regression analysis model, elevated brachial-ankle PWV was found to have a significant odds ratio for elevated serum NT-proBNP levels !125 pg/mL; in addition, elevated radial AI also had a significant odds ratio, and elevated SP2 and PP2 had marginal odds ratios for elevated serum NT-proBNP levels !55 pg/mL (Table 4) .
Discussion
To the best of our knowledge, the present study is the first cross-sectional study to examine the significance of the association of elevated arterial stiffness/abnormal central hemodynamics with minimally elevated serum cTnT levels as compared to that with minimally elevated serum NT-proBNP levels in a middle-aged male worksite cohort.
The cut-off values for minimal elevations of the serum cTnT levels have not yet been clearly established [21] . The percentage of subjects with minimally elevated serum cTnT levels was 6.7% in the Prevention of Renal and Vascular End-stage Disease (PREVEND) study (cut-off value !0.010 ng/mL) [19] , 3.4% in the DH study (cutoff value !0.014 ng/mL) [4] , and 7.4% in the Atherosclerosis Risk in Communities (ARIC) Study (cut-off value !0.014 ng/mL) [5] . In the present study, the prevalence was 3.2% (76/2374) for the cut-off value of !0.010 ng/mL, and 1.1% (26/2374) for the cut-off value of !0.014 ng/mL. The PREVEND study included study subjects with renal dysfunction [18] , and the mean age of the study subjects in the DH study and ARIC study was higher than that in the present study [4, 5] . Aging and renal dysfunction are thought to be factors associated with minimal elevations of the serum cTnT levels [3] [4] [5] [6] , therefore, the prevalence rate of elevated serum cTnT levels in the present study was lower than that in the PREVEND study [19] , DH study [4] , and ARIC study [5] .
The mechanisms underlying minimal elevation of serum cTnT levels have not yet been fully clarified. Bai et al. reported that BMI, body mass index; HR, heart rate; baPWV, brachial-ankle pulse wave velocity; rAI, radial augmentation index; SP1, first peak of the radial pressure waveform (brachial systolic blood pressure); SP2, second peak of the radial pressure waveform; BDP, brachial diastolic blood pressure; PP1, first peak of the radial pressure waveform-diastolic blood pressure; PP2, second peak of the radial pressure waveform-diastolic blood pressure; LDL, serum low-density lipoprotein cholesterol; HDL, serum high-density lipoprotein cholesterol; TG, serum triglyceride; FPG, fasting plasma glucose; UA, serum uric acid level; Scr, serum creatinine level; eGFR, creatinine-based estimated glomerular filtration rate; cTnT, serum level of cardiac troponin T; cTnT !0.014 ng/mL, number and percentage of subjects with cTnT !0.014 ng/mL; cTnT !0.010 ng/mL, number and percentage of subjects with cTnT !0.010 ng/mL; NT-proBNP, serum Nterminal fragment B-type natriuretic peptide level; NT-proBNP !125 pg/mL, number and percentage of subjects with NT-proBNP !125 pg/mL; NT-proBNP !55 pg/mL, number and percentage of subjects with NT-proBNP !55 pg/mL; Percent and no. of, percentage and number of subjects; CVD, subjects with cardiovascular disease (coronary heart disease, heart disease other than coronary heart disease, and/or stroke); CHD, subjects with coronary heart disease; Other heart disease, subjects with heart diseases other than coronary heart disease; Med for HYP, subjects receiving medication for hypertension; Med for DL, subjects receiving medication for dyslipidemia; Med for DM, subjects receiving medication for diabetes mellitus; DM, subjects with diabetes mellitus. Entered solely, parameters entered solely into binary logistic analysis; Entered simultaneously, parameters entered simultaneously into binary logistic analysis; B, non-standardized coefficient; Wald, Wald chi-square; Odds, odds ratio; 95% CI, 95% confidence interval; perSD, as per standard deviation increase; 0/1, negative/positive; BMI, body mass index; SP1, first peak of the radial pressure waveform (brachial systolic blood pressure); PP1, first peak of the radial pressure waveform-diastolic blood pressure; LDL, serum low-density lipoprotein cholesterol; HDL, serum high-density lipoprotein cholesterol; eGFR, creatinine-based estimated glomerular filtration rate; cTnT, serum level of cardiac troponin T; CVD, subjects with cardiovascular disease (coronary heart disease, heart disease other than coronary heart disease, and/or stroke); Med for HYP, subjects receiving medication for hypertension; Med for DL, subjects receiving medication for dyslipidemia; Med for DM, subjects receiving medication for diabetes mellitus; DM, subjects with diabetes mellitus. Entered solely, parameters entered solely into binary logistic analysis; Entered simultaneously, parameters entered simultaneously into binary logistic analysis; B, non-standardized coefficient; Wald, Wald chi-square; Odds, odds ratio; 95% CI, 95% confidence interval; perSD, as per standard deviation increase; 0/1, negative/positive; BMI, body mass index; SP1, first peak of the radial pressure waveform (brachial systolic blood pressure); PP1, first peak of the radial pressure waveform-diastolic blood pressure; LDL, serum low-density lipoprotein cholesterol; HDL, serum high-density lipoprotein cholesterol; eGFR, creatinine-based estimated glomerular filtration rate; cTnT, serum level of cardiac troponin T; CVD, subjects with cardiovascular disease (coronary heart disease, heart disease other than coronary heart disease, and/or stroke); Med for HYP, subjects receiving medication for hypertension; Med for DL, subjects receiving medication for dyslipidemia; Med for DM, subjects receiving medication for diabetes mellitus; DM, subjects with diabetes mellitus.
increased arterial stiffness, as assessed by the carotid-femoral PWV, is associated with minimally elevated serum cTnT levels in elderly subjects (aged >60 years old), but not in middle-aged subjects (aged <60 years old) [11] . Pathophysiological abnormalities (i.e. increased left ventricular afterload, including increased late systolic left ventricular wall stress and impaired coronary blood flow supply) related to increased arterial stiffness/abnormal central hemodynamics may be responsible for elevation of the serum cTnT levels. The AI, SP2, and PP2 are markers of central hemodynamics [12, 15] , and these markers reflect facets of pathophysiological abnormalities different from those reflected by the PWV, a marker of arterial stiffness [12, 15, [22] [23] [24] . SP2 is a marker related to left ventricular afterload, and PP2 is a marker related to left ventricular wasted effort and ejection duration (these abnormalities cause myocardial ischemia) [12, 15, [22] [23] [24] [25] 13 ], which is a major risk factor for heart failure and left ventricular hypertrophy. While the DH study demonstrated that heart failure and left ventricular hypertrophy are associated with minimally elevated serum cTnT levels [4] , Bai et al. did not examine the association of the AI, SP2, or PP2 with the serum cTnT levels [11] . In the present study, not only the brachial-ankle PWV, but also the radial AI, SP2, and PP2 did not show any significant association with the serum cTnT levels. Thus, in the middle-aged male worksite cohort, arterial stiffness/central hemodynamics did not appear to be significant determinants of minimally elevated serum cTnT levels. Several studies have reported that aging, elevated blood pressure, diabetes mellitus, and renal dysfunction are associated with minimally elevated serum cTnT levels [3] [4] [5] [6] , and also with increased arterial stiffness/abnormal central hemodynamics [22, 24] . In the present study, advanced age, elevated BMI, hypertension, and reduced GFR, but not elevated brachial-ankle PWV, SP2, or PP2, were associated with minimally elevated serum cTnT levels. Therefore, conventional risk factors for cardiovascular disease and renal dysfunction might be directly associated with coronary microvascular damage/cardiac myocyte damage, and such damage might also contribute to minimally elevated serum cTnT levels, according to the results of the present study.
The DH study and ARIC study demonstrated that elevated serum cTnT levels and elevated serum NT-proBNP levels are independent predictors of future cardiovascular events [4, 5] . Previously, we demonstrated that elevated PP2, a marker related to central pulse pressure, was associated with elevated serum NTproBNP levels [12] ; similar findings were observed in the present study in that the brachial-ankle PWV and radial AI showed a significant relationship with the serum NT-proBNP levels. Thus, Table 4 Results of binary logistic regression analyses conducted to assess the correlations of markers of arterial stiffness/central hemodynamics with elevated serum cTnT levels and elevated serum NT-proBNP levels. Entered solely, parameters entered solely into binary logistic analysis; B, non-standardized coefficient; Wald, Wald chi-square; Odds, odds ratio; 95% CI, 95% confidence interval; perSD, as per standard deviation increase; baPWV, brachial-ankle pulse wave velocity; rAI, radial augmentation index; SP2, second peak of the radial pressure waveform; PP2, second peak of the radial pressure waveform-diastolic blood pressure.
increased arterial stiffness/abnormal central hemodynamics may contribute, at least in part, to the association of elevated serum NTproBNP levels with cardiovascular events. On the other hand, increased arterial stiffness/abnormal central hemodynamics may not contribute to the known association of minimally elevated serum cTnT levels with cardiovascular events. Our previous study reported that among the markers of arterial stiffness/central hemodynamics, PP2 showed the closest relationship to the serum NT-proBNP levels in healthy middleaged men, not including patients with cardiovascular disease [12] . The present study subjects included patients with cardiovascular disease, which might be one of the plausible reasons why elevated brachial-ankle PWV and radial AI, but not elevated PP2, showed significant odds ratios for elevated serum NT-proBNP levels.
From the clinical perspective, in the present study, elevated serum NT-proBNP levels, but not elevated serum cTnT levels, were associated with cardiovascular disease. In previous studies that reported the usefulness of serum cTnT levels to predict future cardiovascular events, all the study subjects were over 50 years of age [3] [4] [5] [6] . Thus, in middle-aged men, serum cTnT may not be a suitable marker for screening against latent cardiovascular disease in a health check-up program.
Study limitations
(1) This was a cross-sectional study, and a prospective study to examine the interactions among the predictive values of the serum cTnT levels, serum NT-proBNP levels, and markers of arterial stiffness/central hemodynamics for predicting future cardiovascular events is proposed. (2) Although the carotid-femoral PWV and carotid arterial wave analysis are the standards for non-invasive assessment of the arterial stiffness/central hemodynamics [7, 9] , we used brachial-ankle PWV and radial arterial waveform analysis, because of the simplicity of their application to a large number of study subjects [8, 12, 14, 15] . (3) Gender and ethnic differences in the central hemodynamic indices have been reported [14, 25] . On the other hand, the usefulness of serum cTnT to predict future cardiovascular events and/or the prognosis has been demonstrated in a general population consisting of relatively old subjects, subjects with acute pulmonary edema and subjects with acute chest pain [3] [4] [5] [6] 26, 27] . Therefore, evaluations of the associations among the serum cTnT levels, arterial stiffness/central hemodynamics, and the risk/prognosis of cardiovascular disease/the prognosis of cardiovascular disease in women and elderly subjects, and also subjects of other ethnicities and with cardiovascular disease are proposed.
Conclusion
Increased arterial stiffness/abnormal central hemodynamics appeared to be associated with elevated serum NT-proBNP levels, rather than with minimally elevated serum cTnT levels, in the middle-aged male worksite cohort studied. This difference may be one of the plausible explanations for the independence of the predictive values of the two serum markers for future cardiovascular events.
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